FLGT - Fulgent Genetics, Inc.
NEXT EARNINGS:
Feb 27, 2026
(in 2 days)
EPS Est: $0.03
|
Rev Est: $85.4M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$36.00
DETAILS
HIGH:
$36.00
LOW:
$36.00
MEDIAN:
$36.00
CONSENSUS:
$36.00
UPSIDE:
55.91%
Market Cap:
713.77M
Volume:
267,638
Avg Volume:
210,963
52 Week Range:
14.57-31.04
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
0.87
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,313
IPO Date:
2016-09-29
EPS (TTM):
-1.41
P/E Ratio:
-13.08
Revenue (TTM):
283.47M
Total Assets:
1.22B
Total Debt:
8.47M
Cash & Equiv:
55.14M
Rev Growth (5Y):
54.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-6.4%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-07 | $0.14 | $-0.24 | +158.3% | $84.1M | $85.4M | -1.5% |
| 2025-08-01 | $0.07 | $-0.23 | +130.4% | $81.8M | $81.4M | +0.5% |
| 2025-05-02 | $0.04 | $-0.19 | +121.1% | $73.5M | $77.0M | -4.6% |
| 2025-02-28 | $0.04 | $-0.31 | +112.9% | $76.2M | $75.4M | +1.1% |
| 2024-11-08 | $0.31 | $-0.19 | +263.2% | $71.7M | $75.4M | -4.8% |
| 2024-08-02 | $0.15 | $-0.31 | +148.4% | $71.0M | $69.1M | +2.8% |
| 2024-05-03 | $-0.01 | $-0.33 | +97.0% | $64.5M | $65.4M | -1.3% |
| 2024-02-28 | $0.28 | $-0.30 | +193.3% | $70.5M | $66.3M | +6.3% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 283.47M | 289.21M | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M | 18.73M | 18.28M | 9.58M | 1.28M |
| Net Income | (42.71M) | (167.82M) | 143.40M | 507.36M | 214.31M | (411,000) | (5.61M) | (2.51M) | (5.35M) | (8.31M) | (4.28M) |
| EPS | -1.41 | -5.63 | 4.76 | 17.13 | 9.44 | -0.02 | -0.25 | -0.15 | -0.30 | -0.64 | -0.34 |
| Total Assets | 1.22B | 1.24B | 1.39B | 1.28B | 700.46M | 88.76M | 55.02M | 56.95M | 58.04M | 5.83M | 2.12M |
| Total Debt | 8.47M | 15.25M | 38.94M | 21.28M | 15.85M | 2.68M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 55.14M | 97.47M | 79.51M | 164.89M | 87.43M | 11.96M | 6.74M | 6.49M | 7.90M | 489,000 | 172,000 |
| Operating Cash Flow | 21.06M | 27.00M | 253.52M | 538.58M | 140.63M | 5.52M | (675,000) | 1.33M | 4.41M | (969,000) | (4.40M) |
| Free Cash Flow | (19.25M) | 4.80M | 234.75M | 514.73M | 104.12M | 4.33M | (3.51M) | (4.03M) | 617,000 | (3.07M) | (5.13M) |
| FCF per Share | -0.64 | 0.16 | 7.80 | 17.50 | 4.59 | 0.23 | -0.20 | -0.23 | 0.03 | -0.24 | -0.29 |
| Book Value | 1.13B | 1.14B | 1.27B | 1.16B | 569.39M | 82.78M | 52.27M | 54.03M | 54.48M | 5.15M | 1.68M |
| Cash & ST Investments | 258.11M | 424.15M | 526.24M | 450.50M | 299.37M | 28.27M | 37.42M | 41.37M | 46.47M | 489,000 | 172,000 |
| ROC Equity | -0.04 | -0.15 | 0.11 | 0.44 | 0.38 | -0.00 | -0.11 | -0.05 | -0.10 | -1.62 | -2.54 |